Parameter | Method | Sample Type | Significance | |
---|---|---|---|---|
1 |
HLA-B5701 |
PCR |
Blood |
Detects human leukocyte antigen-B (HLA-B) 5701 allele, which is associated with hypersensitivity to the anti-HIV drug abacavir |
2 |
IL28B |
PCR |
Blood |
Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients |
3 |
Statin-induced myopathy |
PCR |
Blood |
Detects a variant in human solute carrier organic anion transporter family member IBI gene in patients who are at higher risk for developing statin-induced myopathy |
4 |
Vitamin K Epoxide Reductase Complex 1 (VKORCI) |
PCR |
Blood |
Detects the most important polymorphism in the Vitamin K Epoxide Reductase Complex 1 (VKORCI) gene associated with interindividual dose requirements for oral anticoagulants |
5 |
CYP2C9 |
Multiplex PCR |
Blood |
Simultaneous detection of CYP2C9 (c.430C>T) and CYP2C9 '3 (c.i 075A>C) polymorphisms to determine the drug response of coumarin-based anticoagulation therapy |
6 |
FCGR |
PCR-Hybridization |
Blood |
Detection of allelic variants of FC gamma-Receptor 2A (HI 31 R) and 3A (Fl 58V) associated with response to IgG antibody therapy |
7 |
PGX-5FU |
PCR-Hybridization |
Blood |
Detection of DPYD allelic variant IVSI 4+1 G>A associated with toxicity of 5-FU therapy |
8 |
PGX- CYP2C19 |
PCR-Hybridization |
Blood |
Testing for CYP2C19 variants *3, *5, *7, *8 and 7 |
9 |
PGX - CYP2D6 |
PCR-Hybridization |
Blood |
Testing for CYP2D6 variants *3, *4 and *6 |
10 |
PGX-HIV |
PCR-Hybridization |
Blood |
Testing for genotypes associated with response to HIV highly active anti-retroviral therapy |
11 |
PGX-Thrombo |
PCR-Hybridization |
Blood |
Testing for CYP2C9 and VKORCI variants associated with anticoagulant dose requirements |
12 |
PGX-TPMT |
PCR-Hybridization |
Blood |
Testing for TPMT variants *2, *3A, *3B and *3C associated with response to thiopurine therapy |